Karen-Sue Carlson

Karen-Sue Carlson

Auto-generated profile, based on publicly available information

Karen-Sue Carlson

Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
CYChao Yang
Chao Yang
JSJason R. Siebert
Jason R. Siebert
RBRobert Burns
Robert Burns
ZGZachary J. Gerbec
Zachary J. Gerbec
BBBenedetta Bonacci
Benedetta Bonacci
Subramaniam MalarkannanSubramaniam Malarkannan
Subramaniam Malarkannan
Natural killer (NK) cells are critical to both innate and adaptive immunity. However, the development and heterogeneity of human NK cells are yet to be fully defined. Using single-cell RNA-sequencing technology, here we identify distinct NK populations in human bone marrow and blood, including one population expressing higher levels of immediate early genes indicative of a homeostatic activation. Functionally matured NK cells with high expression of CX3CR1, HAVCR2 (TIM-3), and ZEB2 represents terminally differentiated status with the unique transcriptional profile. Transcriptomic and pseudotime analyses identify a transitional population between CD56bright and CD56dim NK cells. Finally, a donor with GATA2T354M mutation exhibits reduced percentage of CD56bright NK cells with altered transcriptome and elevated cell death. These data expand our understanding of the heterogeneity and development of human NK cells.

7 February 2013 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PDF file
EREllen K. Ritchie
Ellen K. Ritchie
EFEric J. Feldman
Eric J. Feldman
PCPaul J. Christos
Paul J. Christos
SRSarah D. Rohan
Sarah D. Rohan
CLCatherine B. Lagassa
Catherine B. Lagassa
GRGail J. Roboz
Gail J. Roboz
Treatment options for older patients with acute myeloid leukemia (AML) and for patients with relapsed/refractory AML are limited, and outcomes are poor. Decitabine, a hypomethylating agent, is active in patients with myelodysplastic syndrome (MDS) and AML, but its optimal dose and schedule are unknown. We report the efficacy and safety of repeated 10-day cycles of decitabine 20 mg/m2 administered intravenously over 1 h in 52 newly diagnosed and 102 relapsed/refractory patients. Repeated 10-day cycles of decitabine produced a complete response (CR) in 40% of newly diagnosed older patients with AML, many of whom had adverse prognostic features. The median overall survival (OS) was 318 days but there was prolonged survival in responders of 481 days. Relapsed/refractory patients had a CR rate of 15.7% with a median OS of 177 days. Extramedullary toxicity was mild and the regimen was well tolerated for ongoing post-remission, outpatient maintenance cycles. Responses were durable for over 1 year.

1 April 2011 in Clinical Breast Cancer
Verified
Journal Article
Closed access
KCKaren Carlson
Karen Carlson
AOAllyson J. Ocean
Allyson J. Ocean

1 December 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
KBKaren Barker-Carlson
Karen Barker-Carlson
DLDaniel A. Lawrence
Daniel A. Lawrence
BSBradford S. Schwartz
Bradford S. Schwartz
The serine protease tissue-type plasminogen activator (t-PA) initiates the fibrinolytic protease cascade and plays a significant role in motor learning, memory, and neuronal cell death induced by excitotoxin and ischemia. In the fibrinolytic system, the serpin PAI-1 negatively regulates the enzymatic activity of both single-chain and two-chain t-PA (sct-PA and tct-PA). In the central nervous system, neuroserpin (NSP) is a serpin thought to regulate t-PA enzymatic activity. We report that although both sct-PA and tct-PA rapidly form acyl-enzyme complexes with NSP in vitro, the interactions are short-lived, rapidly progressing to complete cleavage of NSP and regeneration of fully active enzyme. All NSP molecules appear to transit through the detectable acyl-enzyme intermediate and progress to completion of cleavage; no subpopulation that functions as a pure substrate was detected. Likewise, all molecules were reactive, with no evidence of a latent subpopulation. The interactions between NSP and t-PA were distinct from those between plasmin and NSP, wherein the same peptide bond was cleaved but there was no evidence of a detectable plasmin-NSP acyl-enzyme complex. The interactions between t-PA and NSP contrast with the formation of long-lived, physiologically irreversible acyl-enzyme complexes between t-PA and PAI-1, suggesting that the physiologic effect of t-PA-NSP interactions may be more complex than previously thought.

1 December 2010 in Glia
Verified
Journal Article
Closed access
PDF file
KCKaren B. Carlson
Karen B. Carlson
PSPrabhjot Singh
Prabhjot Singh
MFMoses M. Feaster
Moses M. Feaster
ARAnita Ramnarain
Anita Ramnarain
CPConstantine Pavlides
Constantine Pavlides
SSSidney Strickland
Sidney Strickland

10 May 2019 in Blood Advances
Verified
Journal Article
Closed access
PDF file
JIJesus Izaguirre-Carbonell
Jesus Izaguirre-Carbonell
LCLuke Christiansen
Luke Christiansen
RBRobert Burns
Robert Burns
JSJesse Schmitz
Jesse Schmitz
CLChenxuan Li
Chenxuan Li
NZNan Zhu
Nan Zhu
JMJD1C, a member of the lysine demethylase 3 family, is aberrantly expressed in mixed lineage leukemia (MLL) gene-rearranged (MLLr) leukemias. We have shown previously that JMJD1C is required for self-renewal of acute myeloid leukemia (AML) leukemia stem cells (LSCs) but not normal hematopoietic stem cells. However, the domains within JMJD1C that promote LSC self-renewal are unknown. Here, we used clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 nuclease (Cas9) negative-selection screening and identified a requirement for the catalytic Jumonji (JmjC) domain and zinc finger domain for leukemia cell survival in vitro and in vivo. In addition, we found that histone H3 lysine 36 methylation (H3K36me) is a marker for JMJD1C activity at gene loci. Moreover, we performed single cell transcriptome analysis of mouse leukemia cells harboring a single guide RNA (sgRNA) against the JmjC domain and identified increased activation of RAS/MAPK and the JAK-STAT pathway in cells harboring the JmjC sgRNA. We discovered that upregulation of interleukin 3 (IL-3) receptor genes mediates increased activation of IL-3 signaling upon JMJD1C loss or mutation. Along these lines, we observed resistance to JMJD1C loss in MLLr AML bearing activating RAS mutations, suggesting that RAS pathway activation confers resistance to JMJD1C loss. Overall, we discovered the functional importance of the JMJD1C JmjC domain in AML leukemogenesis and a novel interplay between JMJD1C and the IL-3 signaling pathway as a potential resistance mechanism to targeting JMJD1C catalytic activity.